Xponance Inc. Has $2.19 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Xponance Inc. lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,879 shares of the biotechnology company’s stock after selling 838 shares during the quarter. Xponance Inc.’s holdings in United Therapeutics were worth $2,191,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of UTHR. Evergreen Capital Management LLC bought a new position in United Therapeutics during the second quarter worth about $375,000. HighVista Strategies LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth approximately $449,000. Epoch Investment Partners Inc. increased its holdings in shares of United Therapeutics by 6.2% during the second quarter. Epoch Investment Partners Inc. now owns 226,655 shares of the biotechnology company’s stock worth $72,201,000 after purchasing an additional 13,157 shares during the period. 1832 Asset Management L.P. acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $1,562,000. Finally, Profund Advisors LLC raised its position in shares of United Therapeutics by 73.1% in the second quarter. Profund Advisors LLC now owns 12,638 shares of the biotechnology company’s stock valued at $4,026,000 after buying an additional 5,338 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on UTHR shares. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Jefferies Financial Group raised their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Bank of America decreased their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $357.17.

Insider Activity

In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 111,252 shares of company stock valued at $36,939,427. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $357.72 on Friday. The company’s 50 day moving average price is $341.49 and its two-hundred day moving average price is $294.59. The firm has a market capitalization of $15.91 billion, a P/E ratio of 16.91, a P/E/G ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period last year, the business earned $5.24 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 24.84 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.